DBV Technologies unveiled a global restructuring plan that will result in a reduction of more than 200 jobs.

BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.

The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.

Top U.S. Food and Drug Administration regulators said most Americans with allergies should be safe to receive the Covid-19 vaccine developed by Pfizer Inc. and Germany’s Biotech SE.

The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 17-4 to recommend Pfizer and BioNTech’s Covid-19 vaccine for Emergency Use Authorization (EUA) for individuals ages 16 years and older.

UK regulators stated that they received two reports of potential allergic reactions linked to the Covid-19 vaccine from Pfizer and BioNTech, according to the Associated Press.

Sociétés des Produits Nestlé, a part of Nestlé Health Science, acquired the outstanding shares of California-based Aimmune for $2.6 billion in cash following years of increasing its financial position in the food allergy-focused company.

Startup IgGenix Inc. emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions.

The U.S. Food and Drug Administration issued a Complete Response Letter regarding DBV Technologies’ Biologics License Application (BLA) for investigational Viaskin Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.

Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.